Aldeyra Therapeutics Bolsa (NASDAQ: ALDX)

Aldeyra Therapeutics

ALDEYRA THERAPEUTICS INC

Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.

Businessman,Using,A,Mobile,Phone,To,Check,Stock,Market,Data,

Equities

Technicals

Markets

Trading Ideas

ALDX

ALEC

BDTX

CHRS

El sector biotecnológico destaca por un repunte de momentum: descubre qué impulsa a estas acciones y cómo interpretar sus percentiles.

4 acciones biotecnológicas con momentum en máximos semanales según su percentil

Aldeyra Therapeutics, Inc. - Common Stock

Aldeyra Therapeutics Inc

News

Legal

Press Releases

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX

Aldeyra Therapeutics to Participate in the 2025 Jefferies Global Healthcare Conference

Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease

Aldeyra Therapeutics Receives Special Protocol Assessment Agreement Letter from the U.S. Food and Drug Administration for ADX-2191 for the Treatment of Primary Vitreoretinal Lymphoma

Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease

Aldeyra Therapeutics Receives Orphan Designation from the European Medicines Agency for ADX-2191 for the Treatment of Inherited Retinal Dystrophies including Retinitis Pigmentosa

Aldeyra Therapeutics to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Aldeyra Therapeutics Receives Fast Track Designation for ADX‑2191 for the Treatment of Retinitis Pigmentosa

Aldeyra Therapeutics Receives Orphan Designation from the European Medicines Agency for ADX-2191 for the Treatment of Primary Large B-Cell Lymphomas of Immune-Privileged Sites, including Primary Vitreoretinal Lymphoma

Aldeyra Therapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Abeona Therapeutics

AC Immune

Allogene Therapeutics, Inc. - Common Stock

Allogene Therapeutics

Annexon

Arcturus Therapeutics Holdings Inc. - Common Stock

Arcturus Therapeutics

Avalo Therapeutics

Candel Therapeutics

Capricor Therapeutics, Inc. - Common Stock

Capricor Therapeutics

Design Therapeutics

Editas Medicine

Enanta Pharmaceuticals, Inc. - Common Stock

Enanta Pharma

Eupraxia Pharmaceuticals Inc. - Common Stock

Eupraxia Pharmaceuticals

Galectin Therapeutics Inc. - Common Stock

Galectin Therapeutics

Genelux

Humacyte

Immutep Limited - American Depositary Shares

Immutep

Kyverna Therapeutics, Inc. - Common Stock

Kyverna Therapeutics

Larimar Therapeutics, Inc. - Common Stock

Larimar Therapeutics

Mereo BioPharma Group plc - American Depositary Shares

Mereo BioPharma Group

PepGen

ProQR Therapeutics N.V. - Ordinary Shares

ProQR Therapeutics

Silence Therapeutics Plc - American Depository Share

Silence Therapeutics

Tectonic Therapeutic, Inc. - Common Stock

Tectonic Therapeutic

Tenaya Therapeutics

Vanda Pharmaceuticals Inc. - Common Stock

Comments

Aldeyra Therapeutics

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL